Digestive cancers

CL1-95029-002

Open-label, non-randomized, Phase 1b/2 trial investigating the;safety, tolerability, and antitumor activity of S095029 (anti-;NKG2A antibody) as a part of combination therapy in participants;with locally advanced and unresectable or metastatic MSIH/;dMMR gastroesophageal junction /gastric cancer

Open at Saint-Cloud since : 06/02/2025
Target : Adult
Phase : Phase I/II

Trial description

To evaluate the safety and tolerability of the;combination and to identify the recommended;Phase 2 dose (RP2D) of S095029 in;combination therapy;- Incidence of dose-limiting toxicities (DLTs);- Frequency and severity of adverse events (AEs) and;laboratory abnormalities according to National;Cancer Institute Common Terminology Criteria for;Adverse Events (NCI-CTCAE v5.0);- Incidence of AEs leading to dose interruption,;modification, delays and permanent treatment;discontinuation;- Change from baseline to the end of the study in safety;laboratory values and vital signs

Url of the trial